Effects of beta-adrenoceptor stimulation on endothelial nitric-oxide synthase phosphorylation of human umbilical vein endothelial cells

Acta Pharmacol Sin. 2003 Mar;24(3):219-24.

Abstract

Aim: To investigate the effects of isoprenaline on the phosphorylation level of endothelial nitric oxide synthase (eNOS) of human umbilical vein endothelial cells (HUVEC) and to elucidate the regulation mechanisms of beta-adrenoceptor (beta-AR) on eNOS activity.

Methods: HUVEC were exposed to isoprenaline (1 micromol/L) for 30 min, in the absence or presence of selective beta1- or beta2 -adrenoceptor antagonists. eNOS was then isolated by immunoprecipitation using a specific eNOS antibody. eNOS activity was determined by the conversion of L-[3H]arginine to L-[3H]citrulline. The levels of eNOS expression and eNOS phosphorylation were measured by Western blotting.

Results: Treatment of HUVEC with isoprenaline (1 micromol/L) for 30 min caused no measureable change in eNOS expression. However, eNOS activity and serine phosphorylation level were significantly increased (P<0.01). This effect could be abolished by a selective beta2-adrenoceptor antagonist ICI 118551.

Conclusion: Isoprenaline increases eNOS activity of HUVEC, this is mediated by beta2-adrenoceptor and associated with an increase of eNOS serine phosphorylation level.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Agonists / pharmacology*
  • Adrenergic beta-Antagonists / pharmacology
  • Cells, Cultured
  • Endothelial Cells / enzymology*
  • Humans
  • Isoproterenol / pharmacology*
  • Nitric Oxide Synthase / metabolism*
  • Nitric Oxide Synthase Type III
  • Phosphorylation
  • Propanolamines / pharmacology
  • Umbilical Veins / cytology
  • Umbilical Veins / enzymology

Substances

  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Propanolamines
  • ICI 118551
  • NOS3 protein, human
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type III
  • Isoproterenol